Generic Name and Formulations:
Diphtheria and tetanus toxoids, acellular pertussis vaccine, aluminum hydroxide adsorbed; hepatitis B vaccine (recombinant), aluminum phosphate adsorbed; inactivated polio vaccine; susp for IM inj; preservative-free; contains traces of formaldehyde, yeast protein, neomycin, polymyxin B, polysorbate 80.
Indications for PEDIARIX:
Immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus (types 1, 2, and 3) in infants age 6 weeks up to 7yrs (before 7th birthday) born of HBsAg-negative mothers.
Each dose is 0.5mL IM in deltoid or anterolateral thigh. Give 1st dose preferably at 2 months of age (may give as early as 6 weeks of age); then give 2nd dose 6–8 weeks later; then give 3rd dose 6–8 weeks later (preferably 8 weeks between doses). Previously vaccinated with one or more doses of individual components: see literature. Not for use as booster dose.
Anaphylaxis associated with previous dose. Encephalopathy within 7 days after previous pertussis-containing vaccine. Progressive neurological disorders (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy).
Guillain-Barre syndrome within 6 weeks of previous tetanus toxoid-containing vaccine. Fever (≥105°F within 48hrs), persistent inconsolable crying (≥3hrs within 48hrs), shock (within 48hrs), or seizures (within 3 days) after previous DTaP or DTwP vaccine: see literature. Seizure risk (may give antipyretic). Bleeding disorders. Have epinephrine available. Latex allergy (syringes). Immunodeficiency. Pregnancy (Cat.C).
DTaP + HB + IPV.
Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Local reactions (pain, redness, swelling), irritability/fussiness, fever, crying, drowsiness, loss of appetite; rare: seizure, anaphylaxis.
Single-dose vials—10; Single-dose prefilled syringes—5
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Testosterone Prescribing Trends in the United States Between 2002 and 2016
- The Future of Food and Drug Regulation: Trump Administration Proposes Reorganization of FDA, USDA
- Popliteal Sciatic Nerve Block May Increase Time to First Opioid Request in Diabetic Peripheral Neuropathy
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Subclinical Hypothyroidism: Controversies in Testing and Treatment